- Home
- IONS vs RHP Comparison
IONS vs RHP Comparison
Compare IONS & RHP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- RHP
- Stock Information
- Founded
- IONS 1989
- RHP 1991
- Country
- IONS United States
- RHP United States
- Employees
- IONS N/A
- RHP N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- RHP Real Estate Investment Trusts
- Sector
- IONS Health Care
- RHP Real Estate
- Exchange
- IONS Nasdaq
- RHP Nasdaq
- Market Cap
- IONS 6.0B
- RHP 6.3B
- IPO Year
- IONS 1991
- RHP 1991
- Fundamental
- Price
- IONS $30.17
- RHP $91.39
- Analyst Decision
- IONS Buy
- RHP Buy
- Analyst Count
- IONS 19
- RHP 6
- Target Price
- IONS $59.24
- RHP $124.67
- AVG Volume (30 Days)
- IONS 1.5M
- RHP 1.5M
- Earning Date
- IONS 05-06-2025
- RHP 04-30-2025
- Dividend Yield
- IONS N/A
- RHP 5.03%
- EPS Growth
- IONS N/A
- RHP N/A
- EPS
- IONS N/A
- RHP 4.38
- Revenue
- IONS $705,138,000.00
- RHP $2,339,501,000.00
- Revenue This Year
- IONS N/A
- RHP $4.08
- Revenue Next Year
- IONS $25.71
- RHP $5.50
- P/E Ratio
- IONS N/A
- RHP $20.89
- Revenue Growth
- IONS N/A
- RHP 8.75
- 52 Week Low
- IONS $29.61
- RHP $89.01
- 52 Week High
- IONS $52.34
- RHP $121.77
- Technical
- Relative Strength Index (RSI)
- IONS 37.05
- RHP 35.01
- Support Level
- IONS $31.04
- RHP $92.04
- Resistance Level
- IONS $33.76
- RHP $96.91
- Average True Range (ATR)
- IONS 1.16
- RHP 2.67
- MACD
- IONS -0.30
- RHP -0.23
- Stochastic Oscillator
- IONS 10.92
- RHP 23.66
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
About RHP Ryman Hospitality Properties Inc. (REIT)
Ryman Hospitality Properties Inc is a lodging and hospitality real estate investment trust that specializes in upscale convention center resorts and country music entertainment experiences. Its core holdings are Gaylord Opryland Resort & Convention Center; Gaylord Palms Resort & Convention Center; Gaylord Texan Resort & Convention Center; Gaylord National Resort & Convention Center; and Gaylord Rockies Resort & Convention Center. The company has three business segments: Hospitality, which includes Gaylord Hotels properties, the Inn at Opryland, and the AC Hotel, Entertainment which includes the entertainment and media assets comprising OEG, and Corporate and Other, which includes corporate expenses. It derives the vast majority of its revenue from its Hospitality segment.